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Abstract
Background: This study aimed to determine the therapeutic effects of highly active anti-retroviral therapy (HAART) on 
the clinical presentations of HIV related oral lesions (HIV-ROLs) in an adult Nigerian population.
Methods: A 5 month prospective study on HAART naïve HIV positive adults recruited into the HAART program of an 
AIDS referral centre. HIV-ROLs were diagnosed clinically by the EEC Clearinghouse on oral problems related to HIV 
infection. Baseline clinical features of HIV-ROLs was documented by clinical photographs using SONY® 5.2 M Cybershot 
digital camera. Post HAART monthly review was conducted using clinical photographs.
Results: A total of 142 patients were seen. Age range was 19 - 75 years. Mean age was 35.6 ± 10.5 (SD). Eighty (56.3%) 
were females. Prevalence of HIV-ROLs was 43.7%. Oral candidiasis (22.4%) was the most prevalent HIV-ROL. 114 (83.2%) 
patients had clinical AIDS at presentation (CDC 1993). 89.4% were placed on Tenofovir/Emtricitabine +`Nevirapine, 
9.9% on Tenofovir/Emtricitabine + Efavirenz. There was strong decline in the clinical features of oral candidiasis from a 
month of commencing HAART. Oral hairy leukoplakia was slow in responding to HAART. Parotid gland enlargement, 
melanotic hyperpigmentation and Kaposi's sarcoma were more persistent and had slower response to HAART. There 
was no clinical change noticed in linear gingival erythema.
Conclusion: HAART has different clinical effects on HIV related oral lesions depending on the size, duration of 
treatment and etiology of the lesions. HIV-ROLs of fungal origin have the fastest response to HAART. These lesions 
alongside immunologic parameters can be used as indicators of success or failure of antiretroviral therapy.
Background
In recent years, the management of human immunodefi-
ciency virus (HIV) positive individuals has been based on
highly active antiretroviral therapy (HAART) comprising
a combination of nucleoside analogue reverse tran-
scriptase inhibitors and at least one protease inhibitor
and/or one non-nucleoside analogue reverse tran-
scriptase inhibitor [1,2]. HAART induces a marked
reduction of viral replication and increases the CD4+ cell
count. Since the introduction of HAART in the mid-
1990s, it has been accompanied by a reduction in the fre-
quency of many of the secondary events caused by HIV
infection, including some oral lesions [3-5]. The sudden
profound reduction in viral burden and improvement in
cellular immunity achieved with the use of HAART are
the most likely influences on the observed reductions [2].
Oral manifestations of HIV infections are sometimes
the first sign of the infection and often indicate its pro-
g r e s s i o n  t o  A I D S .  T h e y  h a v e  a l s o  b e e n  c o n s i d e r e d  o f
value as indicators of success or failure of antiretroviral
therapy. It has been reported that HAART has a marked
effect on the prevalence and clinical appearance on HIV-
related oral lesions [6]. These effects vary from review of
the literatures.
Since the advent of HAART, studies had shown a
decline in the prevalence of oral lesions associated with
HIV/AIDS. These lesions include: oral candidiasis, hairy
leukoplakia, Kaposi's sarcoma, herpes simplex labiali, and
periodontal disease [1,2,4-9]. Other studies had reported
no change in the prevalence of some of the HIV related
oral lesions such as aphthous ulcers [5], salivary gland
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disease [2], human papillomavirus-associated oral lesions
[1,2] and herpes simplex infection [10]. Oral Warts is one
lesion that had been reported to have a six-fold "striking
increase" with HAART [5]. Complete resolution was
reported for a case of Kaposi's sarcoma in a 52 years old
homosexual male with a primary HIV infection after
being on HAART for 4 months [11]. Nearly all the
reported studies had been conducted in industrialized
countries and literatures concerning the behavior of HIV
related oral lesions in patients undergoing HAART is
scarce [12]. This study therefore aimed to determine the
therapeutic effects of HAART on the clinical presenta-
tions of HIV related oral lesions in an adult Nigerian pop-
ulation.
Materials and methods
The study took place at the adult wing of the AIDS Pre-
vention Initiative for Nigeria (APIN) centre, Jos, Nigeria.
This is a referral center specialized in the diagnosis and
management of HIV infection. Patients examined were
those who have been confirmed to be HIV positive
through western blot and/or the use of double ELISA.
These patients were those recruited into the HAART
program of the centre. The study protocol was approved
by the ethical committee of the Jos University Teaching
Hospital and each patient gave written informed consent.
Inclusion criteria established that patients were
HAART naïve. Oral lesions were diagnosed clinically
according to the criteria established by the European Eco-
nomic Community Clearinghouse on oral problems
related to HIV infection [9]. Oral examinations were per-
formed by a Dental surgeon trained in the identification
of HIV related oral lesions. Where multiple lesions were
seen (in the same patient) at the time of clinical evalua-
tion, each lesion was considered independently for the
analysis.
The baseline clinical status of soft oral tissues of all the
included patients was documented on their first clinical
appearance. The location, clinical characteristics and date
lesion was seen were documented by clinical photo-
graphs. This was by the use of a SONY® 5.2 M Cybershot
digital camera. Pictures were transferred into coded fold-
ers (for each patient) created in a Toshiba Satellite laptop.
The patients were monitored monthly (for 5 months) at
the clinic when they come for their monthly HAART
medications and the same procedure was repeated. No
antifungal therapy was administered post diagnosis of
oral lesions.
For each patient, the following information was also
recorded: age, sex, smoking and alcohol use, clinical stage
of infection (using the clinical categories of the1993
revised CDC classification system for HIV infection),
type of HAART prescribed and the HIV related oral
lesion(s) noticed. Also documented were the CD4 cells
(count/ml) and the HIV RNA copies/ml at baseline, 12
and 24 weeks after.
The effects of HAART on the lesions were recorded as
a decrease in the size of the lesion, resolution, no change
and the appearance of a new lesion (or recurrence).
Effects on the immunologic parameters were based on
the relative changes in the different categories. CD4 cells
counts ≥500/ml was classified as "marginally immunode-
ficient", CD4 cell count of >200 to <500/ml as "mildly
immunodeficient" and CD4 cell count of ≤200/ml as
"severely immunodeficient". Grade 1 classification for
viral load was 'undetectable' to ≤10,000 copies/ml while
Grade 2 was >10,000 copies/ml. Statistical analysis which
includes cross-tabulations, frequencies and Chi - Square
test was done using SPSS software version 15.0.
Results
A total of 142 patients were seen. Age range was 19 - 75
years. Mean age was 35.6 ± 10.5 (SD). 80 (56.3%) were
females. At the time of the clinical examinations, 73.2% of
the patients said they were non drinkers, 18.3% drink
alcoholic beverages occasionally. Also, as regards tobacco
Table 1: Disease Stage for 142 HIV infected Nigerian patients using the 1993 Revised CDC Classification System for HIV 
Infection
CD4+ T cell categories (cells/mm3) Clinical categories
ABC
Asymptomatic, acute 
(primary) HIV
Symptomatic, not A or C 
Conditions
AIDS Indicator Conditions
≥500 A1 (1) B1 (0) C1 (0)
200-499 A2 (10) B2 (12) C2 (16)
<200 A3 (19) B3 (35) C3 (44)
Persons in categories A3, B3, C1, C2, and C3 have AIDS under the 1993 surveillance case definition i.e. 19 + 35 + 44 + 16 = 114. This gives 83.2% 
for the proportion with AIDS (computed with 137 as the total number due to 5 missing CD4 counts)Taiwo and Hassan AIDS Research and Therapy 2010, 7:19
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use, 93% of the patients were non smokers, 5.6% had
stopped smoking while only 2 (1.4%) were active smokers.
A total of 62 (43.7%) patients had at least an oral manifes-
tation of HIV/AIDS. 22 (35.5%) of this number (62) had
multiple lesions with the maximum number noticed per
patient being 4.
According to the 1993 revised CDC classification sys-
tem for HIV infection, 114 (83.2%) patients had clinical
AIDS at presentation (Table 1). The immunologic status
at presentation showed an average CD4 count (cells/ml)
of 148.5 ± 117.5 (SD) and a range of 553. The average viral
load (copies/ml) was 163,831.9 ± 279,964.9 (SD) and a
range of 1,664,700. At the moment of their first oral
examinations, only one patient was classified as "margin-
ally immunodeficient" and 21.1% were in the viral load
group - Grade 1.
Candidosis was the most prevalent oral manifestations
of HIV/AIDS (22.4%). It had equal presentations in both
gender. Erythemathous candidiasis (EC, 10.6%) was the
most common clinical type noticed. Melanotic hyperpig-
mentation (MH) was the next most common presenta-
tion (18.3%) followed by oral hairy leukoplakia (9.9%)
(Table 2). Nearly all the patients (89.4%) were placed on
two NRTIs (Tenofovir/Emtricitabine) plus an NNRTI
(Nevirapine). 14 (9.9%) patients were placed on Tenofo-
vir/Emtricitabine but with a separate NNRTI (Efavirenz).
Only a patient was on the combination of (Lamivudine/
Zidovudine) and a protease inhibitor (Indinivir). Table 3
shows the effects of HAART on the different immuno-
logic classifications of the patients from 'start' to 24
weeks.
Effects of HAART on HIV-related oral lesions
Depending on the extent of the lesions at presentation, all
the available cases of pseudomembraneous candidiasis,
angular cheilitis, erythematous candidiasis (figure 1) and
oral ulcers had disappeared by the third month of obser-
Table 2: Prevalence of oral manifestations of HIV/AIDS in 142 HIV infected Nigerian patients.
Type Male Female Total
Any oral disease
Candidal lesion N % n %N%
Pseudomembraneous Candidiasis 4 2.8 5 3.5 9 6.3
Angular Cheilitis 3 2.1 5 3.5 8 5.8
Erythematous Candidiasis 9 6.3 6 4.2 15 10.6
Total 16 11.2 16 11.2 32 22.4
Linear Gingival Erythema 1 0.7 - - 1 0.7
Oral Hairy Leukoplakia 6 4.2 8 5.6 14 9.9
Herpes Simplex 1 0.7 - - 1 0.7
Melanotic Hyperpigmentation 12 8.5 14 9.9 26 18.3
Oral ulcerations 4 2.8 1 0.7 5 3.5
Kaposi's Sarcoma 3 2.1 2 1.4 5 3.5
Enlarged salivary gland 3 2.1 3 2.1 6 4.2
Xerostomia 5 3.5 1 0.7 6 4.2
Presence of HIV-related oral lesions 30 21.1 32 22.5 62 43.7
Table 3: Effects of HAART on the immunologic status of HIV infected Nigerian patients
CD4 cells counts (cells/ml) Viral loads (copies/ml)
No of patients % of those 
with (≥500)
% of those with 
(200 - 499)
% of those 
with (<200)
No of 
patients
% of those in 
Grade 1 ≤10,000
% of those in Grade 
2 >10,000
Start N = 137 0.7 27.7 71.6 N = 142 21.1 78.9
12 weeks N = 82 6.1 50 43.9 N = 97 84.5 15.5
24 weeks N = 97 6.2 51.5 42.3 N = 85 84.7 15.3Taiwo and Hassan AIDS Research and Therapy 2010, 7:19
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vation. The response was a strong decrease in candidiasis
most especially pseudomembraneous candidiasis whose
resolution had been noticed starting a month after com-
mencing HAART. A new case (recurrence) of
pseudomembraneous candidiasis was noticed 4 months
after the lesion had disappeared (figure 2).
Oral hairy leukoplakia (figure 3) was slow in respond-
ing to HAART. There was no significant clinical change
on some of the lesions in the first month of using
HAART. A gradual decrease in the size of the lesion was
observed for months with eventual disappearance of
some by the end of 5 months.
Parotid gland enlargement (figure 4), melanotic hyper-
pigmentation (figure 5) and Kaposi's sarcoma (figure 6)
w e r e  m o r e  p e r s i s t e n t  a n d  h a d  s l o w e r  r e s p o n s e  t o
HAART. For all the lesions monitored, none was able to
achieve complete resolution during the period of obser-
vation. For the first few months, there was negligible
change in the clinical features of melanotic hyperpigmen-
tation. Gradual decrease in size was also noticed for
parotid gland enlargement and Kaposi's sarcoma. There
was no change observed in the only case of linear gingival
erythema noticed throughout the duration of the study.
Table 4 shows the relationship between the prevalence of
the oral manifestations of HIV/AIDS and the immuno-
logic parameters from the commencement of HAART to
24 weeks.
Discussions
It is well known that HIV -positive patients with CD4+
lymphocyte counts less than 200 cells/ml are severely
immunocompromised and the HIV-positive patient with
viral load greater than 10,000 copies/ml show active vire-
mia [12]. In both Cases, these values are indicators of
progression to AIDS. These markers are used to indicate
success or failure of antiretroviral therapy. Oral manifes-
tations of HIV infections which are sometimes the first
sign of the infection can also indicate its progression to
AIDS. This is because these lesions appear as a result of
declining immune competence. They have also been con-
sidered of value as indicators of success or failure of anti-
retroviral therapy.
With 114 (83.2%) of our patients having frank AIDS at
baseline (CDC 1993), a prevalence of 43.7% was noticed
for HIV related oral lesions. There was an appreciable
immunologic reconstitution in the patients observed at
12 and 24 weeks compared to baseline (Table 3). This we
believe may be responsible for the positive changes
noticed in the clinical features of the HIV-ROLs studied.
During the period of study, HIV-ROLs of fungal origin
(pseudomembraneous, erythemathous candidiasis and
angular cheilitis) experienced significant changes - com-
plete resolution. This change was gradual and became
noticeable by the end of the first month of using HAART.
The rate of resolution also depended on the size of the
lesion at presentation. It has been proposed that this
could be as a result of the effects of HAART on secreted
aspartyl proteinases (SAPs) which are an important viru-
lence factor of candida. This is apart from the improve-
ment in the immunological response of the host from
HAART [13]. Our findings demonstrating a strong
decline in the clinical features of oral candidiasis agrees
with previous reports.
The re-occurrence of a new lesion of pseudomembra-
neous candidiasis 4 months after the resolution of the
same in a female patient may be an evidence of immune
reconstitution inflammatory syndrome (IRIS). 'An IRIS
event is defined as either a first presentation or a para-
doxical worsening of a pre-existing condition after the
initiation of HAART in the presence of rising CD4 counts
and falling HIV-1 RNA levels, if measured'[14]. The CD4
counts (cells/ml) of this patient rose from 73 to 269 while
Figure 1 Erythemathous Candidiasis Patient on: Tenofovir/Emtricit-
abine + Nevirapine
Figure 2 Pseudomembraneous Candidiasis (Re-occurrence) Pa-
tient on: Tenofovir/Emtricitabine + Nevirapine
Figure 3 Oral Hairy Leukoplakia Patient on: Tenofovir/Emtricitabine 
+ Nevirapine
Figure 4 Parotid Gland Enlargement Patient on: Tenofovir/Emtricit-
abine + EfavirenzTaiwo and Hassan AIDS Research and Therapy 2010, 7:19
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the viral load (copies/ml) dropped from 514,298 to 288.
Also, oral candidiasis had been shown to be one of the
lesions evident of IRIS in patients on HAART [14]. Oral
hairy leukoplakia which is of viral origin was slower in its
response to HAART. The effect on OHL may be due to
the direct effect of HAART on the lesion. It may also be
due to the host defense mechanism against opportunistic
organisms such as EBV , the etiologic agent of OHL as a
result of the gradual restoration of CD4+ cells [15]. Clini-
cal features of HIV-ROLs of neoplastic and auto-immune
origin such as oral Kaposi's sarcoma, melanotic hyperpig-
mentation, and salivary gland enlargement were more
protracted in their response to HAART . None of them
achieved complete resolution during the study period.
This might be due to the size of the lesions seen and dura-
tion of treatment (as in this study). A study had reported
a complete resolution of oral Kaposi's sarcoma within 4
months of antiretroviral therapy [11]. This achievement
might be as a result of the size of the lesion. Very few
studies had reported the effects of HAART on melanotic
hyperpigmentation basically due to its low prevalence in
their areas. A study actually reported an increase in the
prevalence of melanotic hyperpigmentation in their
patients on HAART. This was linked with increase mela-
nin production in the epithelium associated with
increased release of a melanin stimulating hormone (a-
MSH) as a result of systemic ketoconazole and zidovu-
dine therapy. Only a patient in our cohort had a combina-
tion of HAART which included zidovudine. Salivary
gland enlargement had been shown in other studies to
actually increase with the advent of HAART [5] while
others had reported no change of the same during treat-
ment with HAART [2,16]. These conflicting findings may
be due to the use of different HAART regimen and differ-
ent treatment durations.
The reduction in the prevalence of HIV related oral
lesions in our study from week 0 to 12 was very signifi-
cant. A Greek study on the effects of PI - HAART on the
prevalence of oral lesions in HIV -1 infected patients also
reported similar findings [17]. However, the prevalence
over the next 12 weeks (to week 24 in our study) was very
minimal. This could be as a result of the lesions of viral,
auto-immune and neoplastic origin which we observed
had a protracted response to HAART.
T h e r e  w e r e  s o m e  l i m i t a t i o n s  t o  t h i s  s t u d y .  I t  w a s
assumed that the patients adhered strictly to the pre-
scriptions given since for the duration of the study, we
Figure 5 Melanotic Hyperpigmentation Patient on: Tenofovir/
Emtricitabine + Efavirenz
Table 4: Prevalence of Oral manifestations of HIV/AIDS in relation to immunologic status
Immunologic 
parameter
week Mean Value ± SD Total number 
of patients
No with HIV/
AIDS oral 
lesions
Prevalence of oral 
manifestations of 
HIV/AIDS (%)
p-value
CD4 counts 
(cells/ml)
0 148.45 ± 117 142* 62 43.7 0.000
12 245.28 ± 144 82 12 14.6
24 253.87 ± 147 97 14 14.4
Viral load 
(copies/ml)
0 163,831.91 ± 
279,964
142 62 43.7 0.000
12 41,122.27 ± 
151,724
97 14 14.4
24 13,900.28 ± 
52,352
85 12 14.1
*A total of 142 patients was seen at start but only the CD4 counts of 135 patients was available
Figure 6 Kaposi's Sarcoma Patient on: Tenofovir/Emtricitabine + 
NevirapineTaiwo and Hassan AIDS Research and Therapy 2010, 7:19
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only had a contact with them once a month. Also, we
could not rule out the possibility of concomitant drug use
as self medication is rife in many parts of the country .
Some of these drugs could also have effects on the HIV-
ROLs. As the study progressed, there was gradual attri-
tion of the patients. This was due to many factors which
includes the demise of some of the patients, inability to
make appointment dates due to lack of funds to travel,
misinterpretation of appointment dates and medical
complications limiting movement. Nevertheless, our
study was able to show the varied effects of HAART on
HIV-ROLs in an adult Nigerian population. The observed
effects were contingent on the size of the lesion, duration
of treatment and the etiology of the lesions. These lesions
alongside immunologic parameters can be used to moni-
tor the responses of patients to HAART.
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